Samsung Biologics said it has invested in U.S.-based biotech venture Generate Biomedicines through its Life Science Fund, aiming to accelerate the development of new technologies and business opportunities in the life sciences sector.
The latest investment marks the eighth investment made by the fund and reflects Samsung’s commitment to discover and explore new opportunities in biopharmaceuticals to address unmet therapeutic needs.
Samsung did not disclose the exact size of the investment, citing contractual reasons.
The Samsung Life Science Fund was jointly established by Samsung C&T, Samsung Biologics, and Samsung Bioepis, with a total investment of 240 billion won ($167 million). It is managed by Samsung Ventures to strategically back innovative biotech companies.
Generate Biomedicines specializes in protein design technology using generative AI and machine learning, supported by an infrastructure to accumulate large-scale datasets for improving AI models and enhancing drug development success rates.
The company’s proprietary generative AI platform, Chroma, enables the rapid design of de novo proteins with desired characteristics and functions, significantly reducing the time required for drug development. Generate is currently developing treatments for cancer, immune disorders, and infectious diseases.
Through this investment, Samsung aims to proactively engage with innovative biotech ventures capable of producing multiple drug candidates. The company also plans to establish a strategic partnership with Generate Biomedicines to support AI-driven drug development. Potential collaborations include contract manufacturing (CMO) services, co-development opportunities, and building a production ecosystem to facilitate the growth of AI-based businesses.
“We have identified Generate Biomedicines’ potential to develop groundbreaking therapies,” Samsung Biologics CEO John Rim said. “By leveraging their strengths in artificial intelligence and machine learning, we aim to foster an ecosystem for collaboration across development, manufacturing, and R&D to drive advancements in next-generation biopharmaceuticals that meet customer needs.”
Generate Biomedicines CEO Mike Nally also said, “Support from key partners like Samsung allows us to continuously evolve our platform, generate high-quality data, and address major health challenges facing humanity.”
In addition to the company’s ongoing clinical programs, it plan to launch three to six additional clinical programs over the next 18 months, transforming its technological potential into tangible outcomes, Nally added.
Samsung’s Life Science Fund has previously invested in biotech companies, including Jaguar Gene Therapy, Latus Bio, and Araris Biotech, as well as local firms such as Aimed Bio and SAIL Biomedicine. The fund has also backed Flagship Pioneering, a venture capital firm that creates and nurtures cutting-edge biotech startups.
This post was originally published on here
